Altogen Biosystems [ Ссылка ] provides the Kidney Targeted Transfection Invivo Kit [ Ссылка ]. Efficient in vivo kidney-targeted delivery of nucleic acids and proteins is enabled with the Altogen® Biosystems Kidney in vivo Transfection Kit.

This product falls into the category of the versatile in vivo transfection kits that Altogen® Biosystems offers. Degradation of cargo molecules is minimized and delivery efficiency is maximized for any negatively charged molecules (DNA, RNA).

-Summary:
Modes of administration:
Systemic intravenous (i.v.) injection
Direct intratumoral (i.t.) injection
Intraperitoneal (i.p.) injection
Kidney-targeted In Vivo Transfection Reagent
Biodegradable lipid liposome-based reagent
Liposome conjugated complexes are stable in serum (16h)
Efficient delivery to the kidney tissue (via systemic administration) and kidney tumors (via intratumoral administration)
Efficient siRNA, shRNA, microRNA, and plasmid DNA delivery
Minimal toxicity
Functionally validated in mice and rats
Applicable for plasmid DNA/siRNA co-injection

-The general process is simple: mix, dilute, vortex and inject!

The hands-on time is less than 30 minutes

With the Altogen Biosystems kidney targeted Kit, less of the delivery cargo is required to achieve maximum mRNA knockdown

-Systemic administration generally translates to clinical research better than localized administration, as diseases can require intravenous or intraperitoneal injections, while local administration can be beneficial over systematic in some cases as it requires lower doses and therefore produces lower side effects.

Altogen Biosystems tissue-targeted in vivo transfection kits also require less siRNA or DNA sample than other commercially available transfection reagents.

-Product Details:
Our kits are easy to use and effective: Mix, dilute, vortex, and inject!
Our kits allow for sustained mRNA knockdown after a single siRNA injection
Target kidney through different administration routes.
There is very low in vivo toxicity and it is safe to use as there is no detectable inflammatory response (ELISA).
Used for preclinical research worldwide!

-Systemic administration (i.v.) of Kidney In Vivo Transfection Reagent conjugated with 80 ug of chemically modified siRNA targeting Lamin A/C mRNA or non-silencing control siRNA following the recommended protocol.
- Intratumoral administration (i.t.) of Kidney In Vivo Transfection Reagent conjugated with 80 ug of chemically modified siRNA targeting Lamin A/C mRNA or non-silencing control siRNA following the recommended protocol.
-Systemic administration (i.v.) of Kidney In Vivo Transfection Reagent conjugated with 80 ug of chemically modified siRNA targeting Lamin A/C mRNA or non-silencing control siRNA following the recommended protocol.

-Product Details:
Contents and Shipping: Kidney in vivo transfection reagent is supplied in liquid form at a concentration of 2.5 mg/ml. Shipped at ambient temperature. Transfection Enhancer reagent is supplied in liquid form at a concentration of 1 mg/ml.
 
Description: Kidney transfection reagent is a nanoparticle-based liposomal formulation optimized for in vivo administration with targeted kidney delivery. Kidney in vivo transfection reagent is a proprietary, animal-origin-free formulation with high transfection efficiency of small RNA (siRNA, shRNA, microRNA) and plasmid DNA.
 
 Product Qualification: Reagents are tested for functional activity, absence of nuclease contamination and microbial contamination.
 
Reagent Properties: Nanoparticle-based liposome conjugated complexes are stable in serum for at least 16 hours. Efficient delivery to the kidney and kidney tumors via systemic administration. Efficient siRNA and plasmid DNA delivery via direct intratumoral injection. Minimal toxicity.

-Potential Clinical Applications of Kidney Targeted Delivery Kit:
Acute kidney injury
Chronic renal diseases (renal fibrosis and autoimmune nephritis)
Other renal diseases, glomerular diseases
Gene therapy to transplanted kidneys in order to improve graft outcomes by reducing potential acute and chronic rejections
Therapeutics to address genetic deficiencies of the native kidney


Connect to Altogen Biosystems:
LinkedIn - [ Ссылка ]
Twitter - [ Ссылка ]
Facebook - [ Ссылка ]

свернуть